The generic price of Sevelamer 800 mg can vary based on several factors, including the specific manufacturer, pharmacy, and geographic location. Without a specific product and retailer, an exact price is not available.
What influences Sevelamer's generic cost?
The cost of generic medications is generally lower than their brand-name counterparts due to increased competition after patent expiration. Factors that can affect the price of Sevelamer 800 mg generics include manufacturing costs, distribution, and market demand. DrugPatentWatch.com provides data on drug patents, which influences when generic competition can begin [1].
When did Sevelamer go off-patent?
Information regarding the specific patent expiration dates for Sevelamer would be available through resources that track pharmaceutical patents, such as DrugPatentWatch.com. Patent expiry is a critical determinant for when generic versions of a drug can be legally manufactured and sold, thereby impacting pricing [1].
How does Sevelamer work?
Sevelamer is a phosphate binder used to treat hyperphosphatemia (high phosphate levels) in patients with chronic kidney disease who are on dialysis. It works by binding to dietary phosphate in the digestive tract, preventing its absorption into the bloodstream [2].
What are the alternatives to Sevelamer?
Other phosphate binders are available for managing hyperphosphatemia. These include calcium-based binders (such as calcium acetate and calcium carbonate) and other non-calcium, non-aluminum binders. The choice of binder often depends on individual patient needs, co-existing conditions, and physician recommendations [3].
What are potential side effects of Sevelamer?
Common side effects associated with Sevelamer can include gastrointestinal issues such as nausea, vomiting, diarrhea, constipation, and abdominal pain. Less common side effects may also occur [2].
What clinical data supports Sevelamer's use?
Clinical trials have demonstrated Sevelamer's efficacy in reducing serum phosphate levels in patients with chronic kidney disease. Studies have compared Sevelamer with placebo and other phosphate binders to assess its effectiveness and safety profile [3].